NCT00162877

Unknown

The Role of CYP2C19 on the Eradication of H. Pylori Infectio...

National Taiwan University Hospital Source

Compare

Other study identifiers

Sponsor study identifier

920505

Secondary identifiers

NTUH93S060

Study Type

interventional

Reported enrollment (type unavailable)

80

Locations

1 country

Sites

1

Timeline

Study Start

June 2004

Date type not reported

This date has not been verified as actual or estimated.

Primary Completion

Not reported

Date not reported

Study Completion

April 2005

Date type not reported

This date has not been verified as actual or estimated.

Brief Summary

The objective of this trial is to find the rationale and the optimal dose and duration of regimen for the eradication of H. pylori infection using different proton pump inhibitors.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: unknown
Reported enrollment (type unavailable): 80 participants
Study completion date: April 2005
Date type not reported
This date has not been verified as actual or estimated.
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
June 2004
Date type not reported
This date has not been verified as actual or estimated.
Study Completion
April 2005
Date type not reported
This date has not been verified as actual or estimated.
First Submitted
September 12, 2005
Actual (reported)
First Posted
September 13, 2005
Actual (reported)

Last Updated: November 23, 2005
Status Verified: January 2004
Last Update Submitted: November 22, 2005

Conditions

Gastritis With H. Pylori Infection Peptic Ulcer With H. Pylori Infection

Keywords

rabeprazole, omeprazole, CYP2C19, H. pylori, PK/PD

Outcome Measures

Primary Outcomes (1)

the role of CYP2C19 on the eradication of H. pylori infection

Secondary Outcomes (1)

implication of PK/PD relationships

Interventions

Rabeprazole vs. EsomeprazoleDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Male and female dyspeptic patients with H. pylori-positive peptic ulcer or gastritis will be recruited at the university hospital in this study.

You may not qualify if:

Sponsors & Collaborators

National Taiwan University Hospital
Otherlead

Study Sites (1)

Department of Internal Medicine, National Taiwan University Hospital

Taipei, 100, Taiwan

Study Officials

Jyh-Chin Yang, M.D.
Department of Internal Medicine, National Taiwan University Hospital
PRINCIPAL INVESTIGATOR

Study Design

Study Type: interventional
Phase: not applicable
Allocation: RANDOMIZED
Masking: NONE
Purpose: TREATMENT
Intervention Model: CROSSOVER
Sponsor Type: OTHER

Study Record Dates

First Submitted

September 12, 2005

First Posted

September 13, 2005

Study Start

June 2004

Date type not reported

This date has not been verified as actual or estimated.

Study Completion

April 2005

Date type not reported

)Pregnant or lactating female;\*2)Patients have endoscopy-based evidence of gastric malignancy, pyloric obstruction, and esophageal stricture requiring dilation, fresh clot, active bleeding, or perforated ulcers;3)Patients requiring anticoagulants or corticosteroid therapy (at dosages greater than the equivalent of prednisone, 10 mg/day);4)Patients with significant impairment of renal function (creatinine\>2mg/dl); liver function impairment (AST and ALT 2x upper limit of normal); severe cardiac disease, e.g. angina pectoris, myocardial infarction, cardiac arrhythmia, congestive heart failure (New York Heart Association Functional Classification III and IV) or acute respiratory disease;5)Patients with a history of esophageal and/or gastric varices;6)Use of other investigational drugs within 30 days prior to the study.

Contact the study team to confirm eligibility.

This date has not been verified as actual or estimated.

Last Updated

November 23, 2005

Record last verified: 2004-01

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT00162877
Data provider: ClinicalTrials.gov
Source updated: 2005-11-23
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:26:02 UTC

Locations

TW(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (1)

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Study Design

Study Record Dates

Source record

Locations